SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2021, with a specific transaction date of January 18, 2021. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares.
- Volume: 3,836.047 shares.
- Price: £13.9340 per share.
- Context: Shares were acquired following the re-investment of dividends paid on January 14, 2021, under the Company's Performance Share Plan subject to a 2-year holding period.
Material Changes
The filing does not disclose material changes to the company's financial position or operations compared to prior periods. It solely documents a routine share acquisition by Ms. E Walmsley, Chief Executive Officer, via dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of a specific equity transaction.
Key Facts for Investor Verification
- Verify the dividend reinvestment mechanism and the 2-year holding period constraints for the Performance Share Plan.
- Confirm the share price of £13.9340 against the London Stock Exchange (XLON) closing price on January 18, 2021.
- Note that this filing does not contain financial performance data for the period.